Douglas Brough - Precigen Senior Research
| PGEN Stock | USD 0.91 0.05 5.81% |
Executive
Douglas Brough is Senior Research of Precigen
| Age | 69 |
| Address | 20358 Seneca Meadows Parkway, Germantown, MD, United States, 20876 |
| Phone | 301 556 9900 |
| Web | https://precigen.com |
Precigen Management Efficiency
The company has return on total asset (ROA) of (0.4232) % which means that it has lost $0.4232 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2932) %, meaning that it created substantial loss on money invested by shareholders. Precigen's management efficiency ratios could be used to measure how well Precigen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to drop to -1.2. In addition to that, Return On Capital Employed is likely to drop to -0.73. At this time, Precigen's Non Currrent Assets Other are very stable compared to the past year. As of the 28th of November 2024, Intangible Assets is likely to grow to about 78.7 M, while Total Assets are likely to drop about 143.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Monic MD | Marker Therapeutics | N/A | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Rafael MD | Aptose Biosciences | 52 | |
| Ingmar MD | Zentalis Pharmaceuticals Llc | 49 | |
| James MD | Corvus Pharmaceuticals | N/A | |
| Mary Sandin | Affimed NV | N/A | |
| Jennifer Buell | Agenus Inc | 49 | |
| BA ACA | Adaptimmune Therapeutics Plc | 54 | |
| Indira Naidu | Immutep Ltd ADR | N/A | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Andrea JD | Zentalis Pharmaceuticals Llc | 43 | |
| Kevin McManus | Syndax Pharmaceuticals | 55 | |
| MSc BBA | Immutep Ltd ADR | N/A | |
| Kimberly Freeman | Zentalis Pharmaceuticals Llc | N/A | |
| RPh PharmD | Affimed NV | 40 | |
| Tushar Mukherjee | CorMedix | N/A | |
| Amy Pooler | Sangamo Therapeutics | N/A | |
| PharmD Rasbach | Zentalis Pharmaceuticals Llc | 44 | |
| Leiv Lea | Corvus Pharmaceuticals | 70 | |
| Nils MD | Agenus Inc | N/A | |
| Steven Closter | Syndax Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.42 |
Precigen Leadership Team
Elected by the shareholders, the Precigen's board of directors comprises two types of representatives: Precigen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Precigen. The board's role is to monitor Precigen's management team and ensure that shareholders' interests are well served. Precigen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Precigen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mr JD, Chief Secretary | ||
| Rob Russell, VP Resources | ||
| Donald Lehr, Chief Secretary | ||
| Rutul Shah, Chief Officer | ||
| Jeffrey Perez, Senior Affairs | ||
| Randal JD, Executive Chairman | ||
| Jeffrey JD, Senior Affairs | ||
| Helen MPH, CEO President | ||
| Steven Harasym, VP Relations | ||
| Douglas Brough, Senior Research | ||
| Helen Sabzevari, CEO President | ||
| Harry Thomasian, Chief Officer | ||
| Bryan Butman, Senior CMC | ||
| Marie Rossi, Vice Communications | ||
| Thomas Reed, Founder Officer |
Precigen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Precigen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.42 | ||||
| Operating Margin | (36.67) % | ||||
| Current Valuation | 228.96 M | ||||
| Shares Outstanding | 292.87 M | ||||
| Shares Owned By Insiders | 10.17 % | ||||
| Shares Owned By Institutions | 63.83 % | ||||
| Number Of Shares Shorted | 16.17 M | ||||
| Price To Earning | (2.06) X | ||||
| Price To Book | 4.55 X |
Pair Trading with Precigen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Precigen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Precigen will appreciate offsetting losses from the drop in the long position's value.Moving together with Precigen Stock
| 0.73 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.68 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Precigen Stock
| 0.58 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.44 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.44 | PHVS | Pharvaris BV | PairCorr |
| 0.42 | OPT | Opthea | PairCorr |
| 0.41 | NAMS | NewAmsterdam Pharma | PairCorr |
The ability to find closely correlated positions to Precigen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Precigen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Precigen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Precigen to buy it.
The correlation of Precigen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Precigen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Precigen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Precigen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Precigen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Precigen Stock, please use our How to Invest in Precigen guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precigen. If investors know Precigen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precigen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Revenue Per Share 0.018 | Quarterly Revenue Growth (0.59) | Return On Assets (0.42) | Return On Equity (1.29) |
The market value of Precigen is measured differently than its book value, which is the value of Precigen that is recorded on the company's balance sheet. Investors also form their own opinion of Precigen's value that differs from its market value or its book value, called intrinsic value, which is Precigen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precigen's market value can be influenced by many factors that don't directly affect Precigen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precigen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Precigen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precigen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.